
Opinion|Videos|January 31, 2025
Advances in Phacoemulsification Techniques
Author(s)Omar R. Shakir, MD, MBA
A panelist discusses how different phacoemulsification technologies, including vacuum-based and fluid-based systems like the Quatera 700, impact surgical efficiency and chamber stability during cataract procedures, emphasizing the importance of optimized fluidics settings for safe outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What phacoemulsification technology do you use in your practice?
- Vacuum based
- Fluid based
- What has your experience been in terms of surgical efficiency and outcomes? What features do you like/dislike?
- What are the key features of the Quatera 700, and how do they contribute to maintaining chamber stability during procedures?
- How can optimizing phaco fluidics settings help to achieve efficient, safe cataract surgery?
Advertisement
Related to this article

In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.

Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.

What the approval of a second targeted biologic means for patients, practice, and the evolving TED treatment landscape
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Demodex blepharitis: Diagnosis, treatment response, and recurrence
3
Myopia control using spectacle lenses with highly aspherical lenslets
4
CHMP recommends ranibizumab biosimilar Fovlussea for retinal disease
5


